leadf
logo-loader
viewIQ-AI Limited

Full interview: More from Imaging Biometrics on the AI deal

IQ-AI Limited’s (LON:IQAI) subsidiary, Imaging Biometrics (IB) recently signed a global distribution deal for imaging analysis software designed to detect chronic liver disease (CLD) and CEO Mike Schmainda tells Proactive why that's been so significant.
Under the agreement with US firm AI Metrics, IB will receive non-exclusive global rights to market and distribute the product, known as LSN. News here too on the brain tumour analysis platform and what other products are in the pipeline.

Quick facts: IQ-AI Limited

Price: 5.8666 GBX

LSE:IQAI
Market: LSE
Market Cap: £8.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

IQ-AI's Imaging Biometrics developing technology that could 'revolutionise...

Michael Schmainda, co-founder and CEO of IQ-AI Limited's (LON:IQAI) subsidiary Imaging Biometrics tells Proactive London's Andrew Scott they're developing a technology that could revolutionise the detection and treatment of brain tumours. IB CAD has been created to pick up cancer cells before...

on 15/7/20

2 min read